» Articles » PMID: 16458842

Management of Liver Tumors in Childhood

Overview
Specialty Pediatrics
Date 2006 Feb 7
PMID 16458842
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Primary neoplasms of the liver occur rarely during childhood and constitute only 0.3-2% of all pediatric tumors. However, they comprise a variety of entities including benign and malignant epithelial, as well as mesenchymal tumors, the most common of these being hepatoblastoma and hepatocellular carcinoma. Clinical presentation, especially in young children is relatively uniform with abdominal enlargement and a painless tumor, and often specific symptoms develop late. Prerequisites for clinical diagnosis are a comprehensive laboratory workup and good quality imaging mainly with ultrasound, as well as CT and/or MRI scans. Histological diagnosis is essential for differential diagnosis and may only be omitted in some hepatoblastoma patients of the typical age (6 months to 3 years) with an excessively elevated serum-alpha-fetoprotein. Surgery is the mainstay of treatment for all benign and malignant liver tumors. Hepatoblastomas mostly respond well to chemotherapy. Therefore, this modality should always be combined with surgical resection in these patients and in many cases can reduce the size of a large tumor to resectability. Prognosis nowadays usually is good in all benign tumors and hepatoblastoma, as well as in some other rare malignancies, but dismal in hepatocellular carcinoma and other chemotherapy non-sensitive malignant tumors.

Citing Articles

Review on Pediatric Malignant Focal Liver Lesions with Imaging Evaluation: Part II.

Dong Y, Cekuolis A, Schreiber-Dietrich D, Augustiniene R, Schwarz S, Moller K Diagnostics (Basel). 2023; 13(24).

PMID: 38132242 PMC: 10743166. DOI: 10.3390/diagnostics13243659.


Review on Pediatric Malignant Focal Liver Lesions with Imaging Evaluation: Part I.

Dong Y, Cekuolis A, Schreiber-Dietrich D, Augustiniene R, Schwarz S, Moller K Diagnostics (Basel). 2023; 13(23).

PMID: 38066809 PMC: 10706220. DOI: 10.3390/diagnostics13233568.


Computed tomography imaging phenotypes of hepatoblastoma identified from radiomics signatures are associated with the efficacy of neoadjuvant chemotherapy.

Chen Y, Froelich M, Tharmaseelan H, Jiang H, Wang Y, Li H Pediatr Radiol. 2023; 54(1):58-67.

PMID: 37982901 PMC: 10776468. DOI: 10.1007/s00247-023-05793-5.


Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as predictive markers in hepatoblastoma.

Xie T, Hou D, Wang J, Zhao S Front Pediatr. 2023; 11:904730.

PMID: 37124183 PMC: 10130377. DOI: 10.3389/fped.2023.904730.


SNORA14A inhibits hepatoblastoma cell proliferation by regulating SDHB-mediated succinate metabolism.

Zhu J, Mao S, Zhen N, Zhu G, Bian Z, Xie Y Cell Death Discov. 2023; 9(1):36.

PMID: 36717552 PMC: 9886955. DOI: 10.1038/s41420-023-01325-0.